Trending Stock News

Lexicon Pharmaceuticals, Inc. (LXRX) EPS Estimated At $-0.43; Fifth Third Bancorp Has Lifted Lauder Estee Cos (EL) Stake By $2.77 Million

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Logo

Analysts expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to report $-0.43 EPS on May, 1.They anticipate $0.10 EPS change or 30.30% from last quarter’s $-0.33 EPS. After having $-0.31 EPS previously, Lexicon Pharmaceuticals, Inc.’s analysts see 38.71% EPS growth. The stock decreased 1.66% or $0.14 during the last trading session, reaching $8.27. About 378,337 shares traded. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has declined 43.19% since April 19, 2017 and is downtrending. It has underperformed by 54.74% the S&P500.

Fifth Third Bancorp increased Lauder Estee Cos Inc (EL) stake by 20.75% reported in 2017Q4 SEC filing. Fifth Third Bancorp acquired 21,816 shares as Lauder Estee Cos Inc (EL)’s stock rose 14.83%. The Fifth Third Bancorp holds 126,968 shares with $16.16M value, up from 105,152 last quarter. Lauder Estee Cos Inc now has $56.09B valuation. The stock decreased 0.40% or $0.61 during the last trading session, reaching $152.5. About 1.83M shares traded. The Estée Lauder Companies Inc. (NYSE:EL) has risen 70.93% since April 19, 2017 and is uptrending. It has outperformed by 59.38% the S&P500.

Among 9 analysts covering Lexicon Pharmaceuticals (NASDAQ:LXRX), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Lexicon Pharmaceuticals had 21 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has “Hold” rating given on Monday, September 28 by Gabelli. Wedbush maintained it with “Outperform” rating and $40 target in Monday, April 16 report. The stock has “Buy” rating by Wedbush on Monday, March 12. Citigroup initiated the shares of LXRX in report on Tuesday, August 2 with “Buy” rating. Wedbush maintained the shares of LXRX in report on Thursday, October 5 with “Buy” rating. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has “Buy” rating given on Friday, September 8 by Stifel Nicolaus. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) earned “Hold” rating by Cowen & Co on Tuesday, August 1. Gabelli downgraded Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) on Friday, September 18 to “Sell” rating. Wedbush maintained the shares of LXRX in report on Monday, August 7 with “Buy” rating. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) earned “Buy” rating by H.C. Wainwright on Friday, October 7.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company has market cap of $873.25 million. The firm offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. It currently has negative earnings. The Company’s orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain.

Fifth Third Bancorp decreased Home Bancshares Inc (NASDAQ:HOMB) stake by 25,622 shares to 957 valued at $22,000 in 2017Q4. It also reduced Spdr Index Shs Fds (RWX) stake by 18,167 shares and now owns 581,679 shares. Allegion Pub Ltd Co (NYSE:ALLE) was reduced too.

Among 31 analysts covering Estee Lauder (NYSE:EL), 23 have Buy rating, 1 Sell and 7 Hold. Therefore 74% are positive. Estee Lauder had 104 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of The Estée Lauder Companies Inc. (NYSE:EL) has “Buy” rating given on Friday, April 28 by RBC Capital Markets. The rating was initiated by Jefferies on Monday, September 28 with “Hold”. The firm has “Buy” rating by Jefferies given on Tuesday, October 10. PiperJaffray upgraded The Estée Lauder Companies Inc. (NYSE:EL) on Thursday, March 2 to “Overweight” rating. On Thursday, January 4 the stock rating was maintained by Wells Fargo with “Buy”. Jefferies maintained the stock with “Hold” rating in Wednesday, April 19 report. The firm has “Buy” rating given on Monday, February 5 by Jefferies. As per Monday, June 13, the company rating was upgraded by CLSA. The rating was maintained by Stifel Nicolaus with “Buy” on Monday, October 24. UBS downgraded the shares of EL in report on Wednesday, January 11 to “Neutral” rating.

Since February 5, 2018, it had 0 insider buys, and 10 sales for $37.14 million activity. Another trade for 13,050 shares valued at $1.80M was made by Haney Carl P. on Monday, February 12. The insider Freda Fabrizio sold 54,610 shares worth $7.69M. 26,039 shares were sold by Trower Alexandra C., worth $3.63M on Thursday, February 15. The insider TRAVIS TRACEY THOMAS sold $700,550. Shares for $3.50 million were sold by O’HARE MICHAEL. MOSS SARA E also sold $4.22M worth of The Estée Lauder Companies Inc. (NYSE:EL) shares. Polcer Gregory sold $6.12 million worth of stock.

Investors sentiment increased to 1.2 in 2017 Q4. Its up 0.17, from 1.03 in 2017Q3. It increased, as 41 investors sold EL shares while 224 reduced holdings. 112 funds opened positions while 206 raised stakes. 188.03 million shares or 1.16% less from 190.23 million shares in 2017Q3 were reported. Bnp Paribas Asset Management Hldg has invested 0.25% in The Estée Lauder Companies Inc. (NYSE:EL). Cambridge Co has 1.53% invested in The Estée Lauder Companies Inc. (NYSE:EL) for 190,594 shares. Raymond James Assocs invested 0.09% in The Estée Lauder Companies Inc. (NYSE:EL). B T Cap Management Dba Alpha Cap Management holds 13,854 shares or 0.83% of its portfolio. Cap Fund Sa holds 0.02% in The Estée Lauder Companies Inc. (NYSE:EL) or 29,304 shares. Amundi Pioneer Asset Management reported 0.1% stake. Impax Asset Management Ltd has 163,214 shares. Gemmer Asset Mngmt Ltd Limited Liability Company has invested 0.01% in The Estée Lauder Companies Inc. (NYSE:EL). Schwab Charles Mgmt owns 0.08% invested in The Estée Lauder Companies Inc. (NYSE:EL) for 792,894 shares. Rhumbline Advisers has 0.1% invested in The Estée Lauder Companies Inc. (NYSE:EL) for 386,285 shares. Telemus Capital Lc holds 0.02% of its portfolio in The Estée Lauder Companies Inc. (NYSE:EL) for 1,805 shares. Sei Invs Communications has 0.09% invested in The Estée Lauder Companies Inc. (NYSE:EL). Meiji Yasuda Life Ins has invested 0.35% in The Estée Lauder Companies Inc. (NYSE:EL). Wafra Invest Advisory Gp owns 70,011 shares or 0.41% of their US portfolio. Bbva Compass Bancshares reported 5,218 shares.

The Estée Lauder Companies Inc. (NYSE:EL) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *